Sex-Based Differences in Clinical Outcomes With Edoxaban Therapy: A Prespecified Analysis of the EPIC-CAD Trial.

BACKGROUND Sex-based differences exist in the characteristics and prognosis of patients with atrial fibrillation (AF) and coronary artery disease (CAD). It is still unknown whether optimal antithrombotic therapy differs by sex. OBJECTIVES This study aimed to evaluate the efficacy and safety of edoxaban therapy in AF with stable CAD, according to sex category. METHODS This prespecified substudy of the EPIC-CAD (Edoxaban Versus Edoxaban With Antiplatelet Agent in Patients With Atrial Fibrillation and Chronic Stable Coronary Artery Disease [EPIC-CAD]) trial compared edoxaban monotherapy with dual antithrombotic therapy (edoxaban plus a single antiplatelet agent). The primary outcome was net adverse clinical events (a composite of death, myocardial infarction, stroke, unplanned revascularization, or clinically relevant bleeding) at 12 months. Median follow-up was 12.0 months (IQR: 11.6-12.9). RESULTS Of 1,040 randomized patients, 238 (22.9%) were women; in the dual-therapy group (n = 516), 110 (21.3%) were women and in the monotherapy group (n = 524), 128 (24.4%) were women. Women were older, had lower body weight, lower creatinine clearance, and more frequently met the edoxaban dose-reduction criteria. The risk of primary outcome was similar between women and men (adjusted HR [aHR]: 1.15; 95% CI: 0.71-1.87; P = 0.559). Edoxaban monotherapy significantly reduced primary events in men compared with dual therapy (aHR: 0.36; 95% CI: 0.23-0.57; P < 0.001), but not in women (aHR: 0.74; 95% CI: 0.33-1.64; P = 0.455). No significant interaction between the randomized treatment and sex was observed (P for interaction = 0.09). CONCLUSIONS Edoxaban monotherapy reduced primary net adverse events at 12 months in men but not in women. No significant interaction with sex was observed. Further research is needed to identify sex-specific antithrombotic strategies for patients with AF and CAD. (Edoxaban Versus Edoxaban With Antiplatelet Agent in Patients With Atrial Fibrillation and Chronic Stable Coronary Artery Disease [EPIC-CAD]; NCT03718559).

• Publication year

  2026

• Venue

  JACC: Asia

• Publication date

  2026-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jacasi.2025.12.022PMID 41762182
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Outcomes by sex in the International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA) trial.

  2024cited by this paper
• Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease.

  2024cited by this paper
• 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

  2023cited by this paper
• Sex Differences in 10-Year Outcomes After Percutaneous Coronary Intervention With Drug-Eluting Stents: Insights From the DECADE Cooperation

  2023cited by this paper
• 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.

  2023cited by this paper
• Sex differences in antiplatelet therapy: state-of-the art

  2023cited by this paper
• The Relationship between Atrial Fibrillation and Coronary Artery Disease: Understanding common denominators.

  2022cited by this paper
• Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial

  2021cited by this paper
• Sex-based outcomes in contemporary antiplatelet therapy trials

  2021cited by this paper
• Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial Fibrillation.

  2021cited by this paper
• Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective: 2021 Update.

  2021cited by this paper
• 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS).

  2020cited by this paper
• Sex Differences in All-Cause Mortality in the Decade Following Complex Coronary Revascularization.

  2020cited by this paper
• Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: JACC State-of-the-Art Review.

  2019cited by this paper
• Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease.

  2019cited by this paper
• Major Bleeding Rates in Atrial Fibrillation Patients on Single, Dual, or Triple Antithrombotic Therapy: Results From a Nationwide Danish Cohort Study

  2019cited by this paper
• Open-Label Randomized Trial Comparing Oral Anticoagulation With and Without Single Antiplatelet Therapy in Patients With Atrial Fibrillation and Stable Coronary Artery Disease Beyond 1 Year After Coronary Stent Implantation: OAC-ALONE Study

  2019cited by this paper
• Patients with atrial fibrillation and coronary artery disease - Double trouble.

  2018cited by this paper
• Sex-Based Differences in Outcomes of Oral Anticoagulation in Patients With Atrial Fibrillation.

  2018cited by this paper
• Balancing thromboembolic and bleeding risk with non‐vitamin K antagonist oral anticoagulants (NOACs): A systematic review and meta‐analysis on gender differences

  2017cited by this paper
• Atrial Fibrillation and Ventricular Arrhythmias: Sex Differences in Electrophysiology, Epidemiology, Clinical Presentation, and Clinical Outcomes

  2017cited by this paper
• Sex-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Observational Research Programme Pilot survey on Atrial Fibrillation.

  2015cited by this paper
• Meta-analysis of gender differences in residual stroke risk and major bleeding in patients with nonvalvular atrial fibrillation treated with oral anticoagulants.

  2014cited by this paper
• Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial.

  2013cited by this paper
• Presentation, management, and outcomes of ischaemic heart disease in women

  2013cited by this paper
• Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients

  2005cited by this paper

• No citing papers are available for this paper.